Literature DB >> 10468904

Endothelial dysfunction in hypopituitary adults with growth hormone deficiency.

L M Evans1, J S Davies, J Goodfellow, J A Rees, M F Scanlon.   

Abstract

OBJECTIVES: Adult hypopituitarism with growth hormone deficiency (GHD) results in reduced exercise capacity, detrimental changes in body composition and lipid profiles and may be associated with an excess cardiovascular mortality. Endothelial dysfunction is an early event in the pathogenesis of atherosclerosis and predisposes to the deposition of unstable atherosclerotic plaques. We have used a noninvasive method to assess endothelial function in the brachial arteries of a group of treated hypopituitary adults with GHD, and a group of healthy age- and sex-matched controls. PATIENTS: Seventeen hypopituitary adults with GHD (13 male, 4 female) aged 26-54 years were studied. Each patient was receiving standard replacement therapy for all other hormonal deficiencies such that all target hormones were maintained in the normal reference range. All observations obtained were compared with those made in age- and sex-matched control subjects. All study subjects had no identifiable risk factors for endothelial dysfunction. MEASUREMENTS: Using an ultrasound vessel wall tracking system, the diameter of the left brachial artery was measured at rest, in response to reactive hyperaemia (endothelium-dependent dilation) and following sublingual glyceryl trinitrate (GTN) (endothelium-independent vasodilatation). We also measured fasting lipids, insulin, plasma glucose, glycated haemoglobin (HbA1c) and IGF-1, and studied the relationship of these parameters to endothelial function.
RESULTS: Flow mediated endothelium-dependent dilatation (FMD), expressed as a percentage change from resting base-line diameter, was significantly impaired in the GHD group (3.70 +/- 2.36% vs. 7.30 +/- 2.42%, P < 0.001). In contrast, GTN-mediated dilatation was similar in both groups. There were no differences in total cholesterol, HDL cholesterol, LDL cholesterol or plasma triglyceride between the groups. Both fasting insulin (27.1 +/- 18.1 vs. 15.89 +/- 6.65 mU/l, P < 0.05) and glycated haemoglobin (HbA1c) levels (5.29 +/- 0.43 vs. 4.91 +/- 0.43%, P < 0.05) were significantly higher in the GHD group. FMD in both groups showed an inverse relationship with total cholesterol (r = -0.58, P < 0.05, GHD and r = -0.55, P < 0.05 controls). However, in the GHD subjects, there was a strong inverse relationship between FMD and LDL-cholesterol (r = -0.81, P < 0.0001). No other relationships were noted between FMD and any other metabolic parameters, or characteristics of GHD.
CONCLUSIONS: Endothelial dysfunction is present in GH deficient adults prior to the onset of overt atherosclerotic disease. The similar glucose yet elevated fasting insulin levels imply a state of relative insulin insensitivity. The strong inverse correlation between endothelial dysfunction and LDL-cholesterol suggests a possible aetiological role for LDL-cholesterol in the pathogenesis of any excess cardiovascular risk associated with adult hypopituitarism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468904     DOI: 10.1046/j.1365-2265.1999.00671.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  23 in total

1.  Effect of growth hormone and estrogen administration on hepatocyte alterations in old ovariectomized female wistar rats.

Authors:  Carmen Castillo; Veronica Salazar; Carmen Ariznavarreta; Elena Vara; Jesus A F Tresguerres
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

2.  Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation.

Authors:  L Groban; M Lin; K A Kassik; R L Ingram; W E Sonntag
Journal:  Growth Horm IGF Res       Date:  2011-03-02       Impact factor: 2.372

Review 3.  Pharmacological Strategies to Retard Cardiovascular Aging.

Authors:  Irene Alfaras; Clara Di Germanio; Michel Bernier; Anna Csiszar; Zoltan Ungvari; Edward G Lakatta; Rafael de Cabo
Journal:  Circ Res       Date:  2016-05-13       Impact factor: 17.367

4.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

Review 5.  L-arginine as a nutritional prophylaxis against vascular endothelial dysfunction with aging.

Authors:  Kevin S Heffernan; Christopher A Fahs; Sushant M Ranadive; Eshan A Patvardhan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-01-06       Impact factor: 2.457

6.  Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Cindy Chen; Jeffrey Wei; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

7.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

8.  Young little mice express a premature cardiovascular aging phenotype.

Authors:  Anilkumar K Reddy; Craig J Hartley; Thuy T Pham; Gretchen Darlington; Mark L Entman; George E Taffet
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

9.  Growth hormone therapy influences endothelial function in children with renal failure.

Authors:  Marc R Lilien; Cornelis H Schröder; Elena N Levtchenko; Hein A Koomans
Journal:  Pediatr Nephrol       Date:  2004-05-15       Impact factor: 3.714

10.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.